|Dr. Vicente J. Anido Jr.||CEO & Chairman||1.13M||N/A||1953|
|Mr. Thomas A. Mitro||Pres & COO||582.78k||N/A||1958|
|Dr. Casey C. Kopczynski||Co-Founder & Chief Scientific Officer||582.51k||2.2M||1961|
|Mr. Richard James Rubino CPA||CFO, Sec. & Treasurer||620.37k||N/A||1958|
|Mr. John W. LaRocca Esq.||Gen. Counsel & Assistant Sec.||576.3k||N/A||1965|
|Mr. Jeffrey Calabrese||Director of Accounting||N/A||N/A||N/A|
|Ms. Ami Bavishi||Director of Investor Relations||N/A||N/A||N/A|
|Andrew Allen||Chief Compliance Officer||N/A||N/A||N/A|
|Mr. Tad Heitmann||Head of Communications||N/A||N/A||N/A|
|Evan Hockman||VP of Sales||N/A||N/A||N/A|
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Aerie Pharmaceuticals, Inc.’s ISS governance QualityScore as of 30 April 2021 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 8; Compensation: 8.